SCHEMBL22866544

SCHEMBL22866544

COc1cc2nccc(Cl)c2s1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ SRC P12931 2/20 0.35
▸ DOT1L Q8TEK3 1/20 0.35
▸ DYRK1A Q13627 1/20 0.34
▸ CGAS Q8N884 1/20 0.34
▸ CCR1 P32246 1/20 0.33
▸ CCR5 P51681 1/20 0.33
▸ CCR8 P51685 1/20 0.33
▸ XPO1 O14980 1/20 0.33
▸ PDGFRB P09619 2/20 0.33
▸ PDGFRA P16234 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ EGFR P00533 1/20 0.32
▸ GRIN3B O60391 1/20 0.32
▸ GRIN1 Q05586 1/20 0.32
▸ GRIN2C Q14957 1/20 0.32
▸ NOS3 P29474 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29560333 1.00 NPC1 (0.37) NPC1RAB9AKMT2ATDP1SRC
SCHEMBL5363061 0.79 HTT (0.35) KMT2AALDH1A1GRIN3BGRIN1GRIN2C
SCHEMBL22866543 0.79 NOS3 (0.35) NPC1RAB9AKMT2ATDP1CCR1
SCHEMBL29560181 0.79 NOS3 (0.35) NPC1RAB9AKMT2ATDP1CCR1
SCHEMBL29808576 0.78 KIT (0.35) NPC1RAB9AKMT2ATDP1SRC
SCHEMBL2209771 0.78 KIT (0.35) NPC1RAB9AKMT2ATDP1SRC
SCHEMBL28375772 0.77 PSMB8 (0.33) NPC1RAB9AKMT2ATDP1
SCHEMBL32683432 0.77 KDM4A (0.32) NPC1RAB9AKMT2ATDP1SRC
SCHEMBL29544655 0.76 GRIN3B (0.36) NPC1RAB9AKMT2ATDP1CCR1
SCHEMBL308582 0.75 MAP3K8 (0.51) NPC1RAB9AKMT2ATDP1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114269756-B 4-Oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds that inhibit EIF4E 效应疗法股份有限公司 2024-05-14 — — CN disclosed
US-20230108594-A1 EIF4E-INHIBITING COMPOUNDS AND METHODS OXFORD FINANCE LLC, AS COLLATERAL AGENT 2023-04-06 — — US disclosed
EP-3994139-A1 EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS Effector Therapeutics Inc. (US) 2022-05-11 — — EP disclosed
WO-2022072634-A1 BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER SCORPION THERAPEUTICS, INC. (US) 2022-04-07 — — WO disclosed
CN-114269756-A 4-oxo-3, 4-dihydropyrido [3,4-D ] pyrimidine compounds inhibiting EIF4E 效应疗法股份有限公司 2022-04-01 — — CN disclosed
US-11286268-B1 EIF4E-inhibiting compounds and methods EFFECTOR THERAPEUTICS, INC. (US) 2022-03-29 — — US disclosed
WO-2021003157-A1 EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS EFFECTOR THERAPEUTICS, INC. (US) 2021-01-07 — — WO disclosed
WO-2021003157-A1 EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS EFFECTOR THERAPEUTICS, INC. (US) 2021-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11286268-B1 EIF4E-inhibiting compounds and methods EIF4E, EIF4EBP1, EIF4A1 NPC1 3170/4885RAB9A 1029/4885KMT2A 2351/4885
US-20230108594-A1 EIF4E-INHIBITING COMPOUNDS AND METHODS EIF4E, EIF4EBP1, EIF4A1 NPC1 3170/4885RAB9A 1029/4885KMT2A 2351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback